CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

BioCardia to Support Development of Potential Cell Therapy Products

BioCardia to Support Development of...

ProPhase Labs Expects Business Expansion with Key Promotions and Addition to Management Team

ProPhase Labs Expects Business...

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

BioCardia to Support Development of Potential Cell Therapy Products

BioCardia to Support Development of...

ProPhase Labs Expects Business Expansion with Key Promotions and Addition to Management Team

ProPhase Labs Expects Business...

Opterion Health Hires Additional Management Personnel

Life Sciences Review Life Sciences Review | Thursday, September 30, 2021
Tweet

Mylène Fleurant, Peter Reinemer, Daniel Lustenberger, and Ulrike Grimm join Opterion’s management team.


FREMONT, CA: Opterion Health AG, a nephrology firm focused on PD innovation, strengthens its executive team, including Daniel Lustenberger as Chief Financial Officer (CFO) and Peter Reinemer as Chief Technology Officer (CTO). Mylène Fleurant has been named Director of Quality, and Ulrike Grimm has been named Director of Project Management. Andreas Schmidt, who will succeed Daniel Lustenberger as CFO, will remain a partner at Opterion Health.


Daniel Lustenberger, CFO


Daniel Lustenberger is an accomplished international finance, accounting, and management consulting executive who will join Opterion Health as Chief Financial Officer in September 2021. He is a certified public accountant in Switzerland, holds an Executive MBA from IMD in Lausanne, and has over 20 years of life sciences and technology expertise.


Peter Reinemer, Chief Technology Officer


Peter Reinemer has worked in the pharmaceutical and biotechnology industries for 30 years. He began his career with Bayer Pharma, where he worked in discovery research for nearly a decade in Germany and Japan.


Mylène Fleurant, Head of Quality


Mylène Fleurant spent over two decades in the life sciences business, heading for quality assurance (QA). She spent ten years at Novartis as Region Head Quality Europe and at Merck Serono implementing global quality systems. Before establishing her consulting firm in 2019, Mylène worked as Global Head of Quality Assurance at Novimmune and as Vice President of Quality Affairs at Alvotech.


Ulrike Grimm, Head of Project Management


Opterion Health hired Ulrike Grimm in June 2020 to build project excellence for the company’s development program. Ulrike began her career as a sales representative for Sanol Pharma before joining Merck KGaA in 1997. 


She held increasing levels of responsibility, beginning as team leader for research and development projects and progressing to product leader for Merck’s second commercial oncology medicine.


Björn Englund, CEO of Opterion Health, comments, “Opterion Health is at a critical phase in its growth strategy, and these key appointments will help us to accelerate the commercialization of our innovative PD solution, which is designed to decrease metabolic challenges, particularly for the estimated 45 percent of dialysis patients who also suffer from diabetes but also for the non-diabetic patients.”


 David Ebsworth, Chairman of Opterion Health, says, “I am grateful to Andreas Schmidt for his outstanding contribution to the success of Opterion Health, which is now well-financed and on track to establish a new standard in peritoneal dialysis. As we strive to complete preclinical work and to enter Phase 1 studies, it is essential to have the best possible team in place and I am delighted to welcome Daniel, Mylène, Peter and Ulrike. Their specialist experience and expertise will greatly assist Opterion Health in achieving its goal of bringing much-needed innovation to dialysis patients, improving their quality of life and enabling them to manage the treatment in their own home.”


Opterion Health is creating the first substantial advance in Parkinson’s disease in over two decades, intending to increase patients’ quality of life and independence. The invention will keep the Peritoneum in place for a more extended amount lowering the danger of hospitalization and scantly reducing dialysis-related healthcare expenses. Earlier this year, the company closed a bridge financing round and opened new premises in Muttenz, Baselland. Opterion Health has appointed Björn Englund, a renowned expert in dialysis, as CEO to assist in preparing for the start of clinical studies in the next one to two years.


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue

Read Also

Everything You Need to Know About Medical Lab Equipment and their Applications

Everything You Need to Know About Medical Lab Equipment and their Applications

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks To Buy In 2022

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial
How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural Genome Editing

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/opterion-health-hires-additional-management-personnel-nwid-581.html